Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BGI and H3 Biomedicine to Sequence Pre-Clinical Cancer Models

publication date: Mar 22, 2013
BGI-Shenzhen and H3 Biomedicine of Cambridge, MA have agreed to develop genomic sequencing data from pre-clinical cancer models. The research is designed to identify and validate recurrent gene mutations that are potential targets for drug therapies. BGI and H3 will share their findings with the global research community after the data analysis is completed. Earlier this week, ChinaBio® Today published an interview with Jun Wang, PhD, the CEO of BGI. Dr. Wang declared that pure science was always the motivating force behind the company’s alliances. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital